Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.05
$5K47.6115,596 shs10,000 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
+100.0%		$0.02
$0.00
▼
$0.11
$32K-0.4430,237 shs10,910 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.01
$0.00
$0.00
▼
$0.50
$20K3892.082,773 shs609 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.07
$0.01
$0.00
▼
$1.50
$63K-1.99727 shs23 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00%0.00%0.00%0.00%-50.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-40.00%+200.00%-99.14%-99.56%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
+12.00%+11,100.00%+5,500.00%+11.44%+11,100.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+450.00%+16,400.00%+494.59%+450.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.05
$5K47.6115,596 shs10,000 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
+100.0%		$0.02
$0.00
▼
$0.11
$32K-0.4430,237 shs10,910 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.01
$0.00
$0.00
▼
$0.50
$20K3892.082,773 shs609 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.07
$0.01
$0.00
▼
$1.50
$63K-1.99727 shs23 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00%0.00%0.00%0.00%-50.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-40.00%+200.00%-99.14%-99.56%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
+12.00%+11,100.00%+5,500.00%+11.44%+11,100.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+450.00%+16,400.00%+494.59%+450.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$17.42M0.00N/AN/A$14.02 per share0.00
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.14N/AN/A($11.07) per share-0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-$30.37M-$0.02N/AN/AN/AN/AN/AN/A11/2/2026 (Estimated)
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$17.90M-$7.56N/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2026 (Estimated)

Latest ARDS, CLVR, TRVN, and BPTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026N/A
Trevena, Inc. stock logo
TRVN
Trevena
-$50.00N/AN/AN/A$0.78 millionN/A
11/2/2026N/A
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-$0.5960N/AN/AN/A$0.27 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
9.65%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
6.92%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
5.50%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
8.20%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
3753.32 million50.39 millionNot Optionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
2961.76 million1.61 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
23959,000841,000No Data

Recent News About These Companies

Trevena stock held at USD 0.01 as volume reached 257 shares
October 6, 2026  |  ad-hoc-news.deA
Trevena (NASDAQ:TRVN) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090708
Trevena stock holds near its yearly range as trading data reset
September 22, 2026  |  ad-hoc-news.deA
Trevena Inc.
May 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/TRVN/financials
Trevena Restructures China Royalty Rights to Exit Debt
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-restructures-china-royalty-rights-to-exit-debt?utm_source=marketbeat.com&utm_medium=referral
Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored
July 8, 2025  |  msn.comhttps://www.msn.com/en-us/sports/mlb/softball-conrad-weiser-s-alex-trevena-earns-statewide-player-of-the-year-award-5-other-berks-players-honored/ar-AA1IcIZz
Trevena, Inc. (TRVN) - Yahoo Finance
June 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TRVN/press-releases/
Trevena Enters Securities Exchange Agreement with Investor
May 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-enters-securities-exchange-agreement-with-investor?utm_source=marketbeat.com&utm_medium=referral
Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win
April 11, 2025  |  readingeagle.comR
Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater
March 9, 2025  |  msn.comhttps://www.msn.com/en-us/music/news/vanessa-hudgens-and-oliver-trevena-appear-at-expo-west-for-caliwater/ar-AA1Axb5h
JMP Securities downgrades Trevena (TRVN) to a Hold
December 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jmp-securities-downgrades-trevena-trvn-to-a-hold-1034177267
‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment
December 16, 2024  |  yahoo.comhttps://www.yahoo.com/entertainment/plane-actor-oliver-trevena-signs-153000870.html
Lyme Regis town councillor John Trevena stand down
December 11, 2024  |  bridportnews.co.ukB
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
December 10, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2381592/trevena-trvn-could-find-a-support-soon-here-s-why-you-should-buy-the-stock-now?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2381592
Trevena appoints new financial chief
November 29, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/trevena-appoints-new-financial-chief-93CH-3745129
Trevena Appoints Katrine Sutton as New CFO
November 27, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-appoints-katrine-sutton-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
HC Wainwright & Co. Downgrades Trevena (TRVN)
November 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-trevena-trvn/ar-AA1u9FYi
Trevena, Inc. Navigates Financial Challenges and Strategic Changes
November 9, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/trevena-inc-navigates-financial-challenges-and-strategic-changes/ar-AA1tMJqv
Chester County biopharm firm's latest layoffs impact its C-suite
November 7, 2024  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2024/11/07/trevena-chesterbrook-layoffs-c-suite-pain-medicine.html
Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review
November 7, 2024  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
An oil tanker anchored near a port terminal with storage tanks and hills visible in the background.
The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
By Thomas Hughes | September 17, 2026
Boeing MQ-25 unmanned aircraft parked on a tarmac near a Lockheed Martin missile launcher and naval vessel.
Lockheed's Stock Hasn't Priced In Its Own Backlog—Boeing's Might Already Have
By Ryan Hasson | September 23, 2026
Aridis Pharmaceuticals stock logo

Aridis Pharmaceuticals NASDAQ:ARDS

$0.0001 0.00 (0.00%)
As of 02:37 PM Eastern

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0006 +0.00 (+100.00%)
As of 01:43 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Clever Leaves stock logo

Clever Leaves NASDAQ:CLVR

$0.01 0.00 (0.00%)
As of 10/13/2026 01:03 PM Eastern

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.07 0.00 (0.00%)
As of 10/13/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas